<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-40 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-40</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-40</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-3.html">extraction-schema-3</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <p><strong>Paper ID:</strong> paper-056885958634c163621f83b98c91636a2a0f401d</p>
                <p><strong>Paper Title:</strong> <a href="https://www.semanticscholar.org/paper/056885958634c163621f83b98c91636a2a0f401d" target="_blank">Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk</a></p>
                <p><strong>Paper Venue:</strong> Neurology</p>
                <p><strong>Paper TL;DR:</strong> Alzheimer-specific neuroprotection is deduced, because the effect is attenuated or eliminated when considering less-specific diagnoses such as AD with another diagnosis (any AD) or all-cause dementia.</p>
                <p><strong>Cost:</strong> 0.014</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e40.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e40.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>NMSC–AD (EAS)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Nonmelanoma skin cancer associated with reduced Alzheimer disease risk (Einstein Aging Study)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>Population-based longitudinal finding from the Einstein Aging Study that prevalent nonmelanoma skin cancer (NMSC) is associated with a substantially reduced hazard of developing clinically diagnosed Alzheimer disease (AD) as the sole diagnosis, with attenuation for broader dementia outcomes.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Nonmelanoma skin cancer (NMSC; basal cell carcinoma and squamous cell carcinoma as reported by participants)</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Alzheimer disease (AD); also analyzed any AD (probable/possible and mixed AD/vascular) and all-cause dementia</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>inverse correlation (specific to NMSC vs 'only AD'); attenuated or nonsignificant for 'any AD' and all-cause dementia</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Einstein Aging Study (N = 1,102; mean age ~79 y; mean follow-up 3.7 y). Baseline NMSC: 109; incident NMSC during follow-up: 32 (141 total NMSC cases). Incident dementia: 126 (76 'only AD'; 24 mixed AD/VaD; 26 other). Primary adjusted result (Model 3: sex, education, occupation, hypertension, diabetes, coronary heart disease): hazard ratio (HR) for developing only AD associated with NMSC = 0.21 (95% CI 0.051–0.87), p = 0.031. Any AD: HR = 0.50, p = 0.11 (nonsignificant trend). All-cause dementia: HR = 0.68, p = 0.24 (nonsignificant). When APOE ε4 allele count was included (Model 4, n=769), only-AD HR = 0.18 (95% CI 0.024–1.34), p = 0.094 (magnitude similar but nonsignificant, likely reduced power). Additional null/negative results: history of any cancer (not limited to NMSC) showed no significant protective effect (Model 3: all-cause dementia HR 0.85 p = 0.44; any AD HR 0.74 p = 0.23; only AD HR 0.69 p = 0.21).</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Paper enumerates several biologically plausible mechanisms linking lower AD risk to cancer or NMSC: differential DNA methylation patterns (altered propensity to methylate DNA), differential activity of tumor suppressor gene p53 (cancer suppression vs neuronal vulnerability), altered Pin1 activity (prolyl isomerase implicated in both tau/amyloid biology and cell cycle control), dysregulation of Wnt signaling, and mechanisms involving γ-secretase/Notch1 signaling (γ-secretase modulation affects APP processing and trials modulating γ-secretase increased NMSC incidence). The authors discuss these as candidate molecular explanations rather than proving any single mechanism.</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>APOE (APOE ε4 alleles were used as covariate in adjusted models; not proposed as the mechanistic link here), TP53 (p53) — discussed as tumor suppressor with potential opposite roles in cancer versus neurodegeneration, PIN1 (peptidyl-prolyl cis-trans isomerase NIMA-interacting 1) — implicated in neurodegeneration and cancer biology, NOTCH1 — discussed in context of γ-secretase/Notch signaling and skin tumor suppression. (Gene mentions derive from discussion and referenced literature.)</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>γ-secretase complex (enzyme that cleaves APP and Notch substrates) — implicated by clinical trial and animal data; p53 protein (tumor suppressor; apoptosis/cell-cycle regulation); Pin1 protein (peptidyl-prolyl isomerase affecting tau and APP-related pathways); Notch1 receptor protein (Notch signaling implicated in skin tumor suppression and differentiation).</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>γ-secretase/Notch signaling, Wnt signaling pathway, tumor-suppressor pathways (p53-related), epigenetic regulation (DNA methylation).</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Differential regulation of cell proliferation versus cell death/tau/amyloid processing; epigenetic regulation (DNA methylation) affecting gene expression; proteolytic processing of APP by γ-secretase; tumor suppression and cell-cycle control (p53, Pin1); Notch-mediated differentiation in epidermis.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>Supportive/explanatory experimental evidence cited in the paper: (a) Clinical trial observation — interruption of the γ-secretase inhibitor semagacestat (for AD) was associated with increased rates of NMSC (Cummings 2010), suggesting γ-secretase modulation affects skin tumor biology; (b) Mouse/experimental data — moderate reduction of γ-secretase attenuates amyloid burden and limits mechanism-based liabilities (Li et al. 2007), linking γ-secretase activity to amyloid pathology; (c) Notch1 functions as a tumor suppressor in mouse skin (Nicolas et al. 2003), providing a mechanistic bridge between γ-secretase/Notch signaling and skin cancer; (d) Hypothesis paper proposing DNA methylation differences as basis for inverse AD–cancer association (Tremolizzo et al. 2006). The present study itself provides observational epidemiologic evidence (hazard ratios above) but no direct molecular experiments.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Several findings and caveats challenge a universal inverse relationship: (1) In this study the inverse effect is specific to 'only AD' and is attenuated or absent for 'any AD' and all-cause dementia, and for 'any cancer' there was no significant protective effect; (2) Racial heterogeneity reported in prior work: in whites prior cancer conferred reduced AD risk, whereas in African Americans cancer was associated with increased AD risk (reported in Roe et al. 2010); (3) Small numbers: only 2 individuals with NMSC developed 'only AD' in this cohort, limiting robustness; (4) Potential confounding (education, socioeconomic status, physical activity, UV exposure) and measurement limitations (self-reported NMSC, possible misclassification with melanoma) could bias results; (5) When APOE ε4 was included, statistical significance was lost though point estimate magnitude remained similar, suggesting limited power or confounding.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Epidemiological study — population-based prospective longitudinal cohort (Einstein Aging Study)</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>In the Einstein Aging Study, prevalent nonmelanoma skin cancer was associated with a significantly reduced hazard of developing Alzheimer disease as the sole diagnosis (Model 3 HR = 0.21, 95% CI 0.051–0.87, p = 0.031); the effect is attenuated and nonsignificant for broader diagnostic categories (any AD, all-cause dementia) and is not seen when analyzing history of any cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk', 'publication_date_yy_mm': '2013-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
            <div class="extraction-instance-container" id="e40.1">
                <h3 class="extraction-instance">Extracted Data Instance 1 (e40.1)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of inverse correlations between cancer and neurodegenerative diseases, including the specific diseases involved, proposed molecular mechanisms, shared pathways or genes, and evidence supporting or challenging the inverse relationship.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>Cancer–AD inverse (literature mentions)</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Previously reported inverse association between cancer (various types, particularly skin cancer) and Alzheimer disease</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>The paper cites multiple prior epidemiological reports that describe an inverse relationship between cancer and AD (reduced cancer incidence in AD patients or reduced AD incidence in persons with prior cancer), with some specificity to AD versus vascular dementia and with race-specific heterogeneity.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Alzheimer disease and cancer.</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>mention</td>
                        </tr>
                        <tr>
                            <td><strong>cancer_type</strong></td>
                            <td>Various cancers (general 'any cancer' findings in cited studies), with special emphasis on skin cancer / nonmelanoma skin cancer in some reports</td>
                        </tr>
                        <tr>
                            <td><strong>neurodegenerative_disease</strong></td>
                            <td>Alzheimer disease (AD); contrasted with vascular dementia (VaD)</td>
                        </tr>
                        <tr>
                            <td><strong>correlation_type</strong></td>
                            <td>inverse correlation reported in several prior epidemiologic studies (reduced cancer incidence among AD patients and trends toward reduced AD incidence among persons with prior cancer); however, results vary by cancer type, dementia subtype, and race</td>
                        </tr>
                        <tr>
                            <td><strong>epidemiological_evidence</strong></td>
                            <td>Cited prior findings include: Washington University AD Research Center observed reduced incidence of cancer in participants with prevalent AD and a nonsignificant trend toward lower incidence of AD in persons with baseline history of cancer; skin cancer in particular accentuated the protective effect (Refs: Roe et al. 2005; Behrens et al. 2008). Cardiovascular Health Study data found AD, but not vascular dementia, was associated with reduced risk of future cancer hospitalization (Roe et al. 2010). The paper notes racial differences: in whites prior cancer diagnosis conferred reduced AD risk, whereas in African Americans prior cancer was associated with increased AD risk (Roe et al. 2010). Specific effect sizes from those cited papers are not reproduced in this text.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_mechanism</strong></td>
                            <td>Cited hypotheses in the literature include differential DNA methylation propensities, altered activity of tumor suppressors such as p53, dysregulation of Pin1, changes in Wnt signaling, and γ-secretase/Notch pathway involvement — all hypothesized to produce discordant risks for proliferative diseases (cancer) vs neurodegenerative processes (AD).</td>
                        </tr>
                        <tr>
                            <td><strong>genes_involved</strong></td>
                            <td>TP53 (p53), PIN1, APOE discussed in the literature context; pathway-level involvement of NOTCH1 and components of the γ-secretase complex; no novel gene-level associations introduced in this paper beyond literature citation.</td>
                        </tr>
                        <tr>
                            <td><strong>proteins_involved</strong></td>
                            <td>γ-secretase complex, Notch1 receptor, p53 protein, Pin1 protein — all cited as relevant in prior studies or reviews referenced by the authors.</td>
                        </tr>
                        <tr>
                            <td><strong>pathways_involved</strong></td>
                            <td>Wnt signaling, Notch/γ-secretase signaling, tumor-suppressor pathways (p53-related), epigenetic regulation (DNA methylation).</td>
                        </tr>
                        <tr>
                            <td><strong>cellular_process</strong></td>
                            <td>Epigenetic regulation (DNA methylation) differing between cancer-prone and neurodegeneration-prone phenotypes; divergent regulation of cell proliferation/cell-cycle control and neuronal protein homeostasis/APP processing.</td>
                        </tr>
                        <tr>
                            <td><strong>experimental_evidence</strong></td>
                            <td>The paper references external studies as experimental or clinical evidence: interruption of the semagacestat (γ-secretase inhibitor) trial was associated with increased NMSC incidence (Cummings 2010); animal studies show γ-secretase modulation affects amyloid burden (Li et al. 2007); Notch1 tumor-suppressor function in mouse skin (Nicolas et al. 2003). These are cited to support biological plausibility rather than provide direct proof of an inverse epidemiologic relationship.</td>
                        </tr>
                        <tr>
                            <td><strong>counter_examples</strong></td>
                            <td>Not all studies are consistent: prior-cancer association with AD differs by race in cited work (increased AD risk in African Americans with cancer in one report); some cohorts show no association for non-AD dementias (e.g., no reduced risk for VaD), and analyses of 'any cancer' in the present cohort showed no significant protective effect. Measurement issues and confounders limit generalizability.</td>
                        </tr>
                        <tr>
                            <td><strong>study_type</strong></td>
                            <td>Literature/epidemiology mentions (prior cohort studies, clinical trial observations, animal experiments and review/hypothesis papers cited)</td>
                        </tr>
                        <tr>
                            <td><strong>key_finding</strong></td>
                            <td>Multiple prior studies have reported an inverse association between cancer and Alzheimer disease (often driven or accentuated by skin cancers), and the present paper cites these findings to contextualize its NMSC–AD association and to motivate mechanistic hypotheses (epigenetic, p53/Pin1, Wnt, γ-secretase/Notch).</td>
                        </tr>
                        <tr>
                            <td><strong>source_info</strong></td>
                            <td>{'paper_title': 'Nonmelanoma skin cancer is associated with reduced Alzheimer disease risk', 'publication_date_yy_mm': '2013-05'}</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Alzheimer disease and cancer. <em>(Rating: 2)</em></li>
                <li>Inverse association between cancer and dementia of the Alzheimer's type. <em>(Rating: 2)</em></li>
                <li>Cancer linked to Alzheimer disease but not vascular dementia. <em>(Rating: 2)</em></li>
                <li>What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? <em>(Rating: 2)</em></li>
                <li>Is the inverse association between Alzheimer's disease and cancer the result of a different propensity to methylate DNA? <em>(Rating: 2)</em></li>
                <li>Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. <em>(Rating: 2)</em></li>
                <li>Notch1 functions as a tumor suppressor in mouse skin. <em>(Rating: 2)</em></li>
                <li>Gamma-secretase and human disease. <em>(Rating: 2)</em></li>
                <li>Gamma-secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>